title: Neoadjuvant or adjuvant therapy for gastric cancer.
abstract: Currently, there is no international consensus on the best treatment regimen for patients with advanced resectable gastric carcinoma. In the United States, where a limited lymph-node dissection is frequently performed, adjuvant chemoradiotherapy after surgery is the standard treatment. In Europe, intensified perioperative chemotherapy is commonly administered. In Japan and South Korea, postoperative S-1-based adjuvant chemotherapy after surgery with D2 lymph-node dissection is the standard treatment. Several ongoing trials are currently evaluating the optimal sequence of chemotherapy, radiotherapy, and surgery, as well as the place of targeted therapeutic agents in the treatment of advanced gastric carcinoma.
authors: Laurent Quéro, Sophie Guillerm, Christophe Hennequin, Department of Radiation Oncology, Saint Louis Hospital, 75010 Paris, France.
authors: Laurent
authors: L
authors: Quéro
authors: Laurent Quéro, Sophie Guillerm, Christophe Hennequin, Department of Radiation Oncology, Saint Louis Hospital, 75010 Paris, France.
authors: Sophie
authors: S
authors: Guillerm
authors: Laurent Quéro, Sophie Guillerm, Christophe Hennequin, Department of Radiation Oncology, Saint Louis Hospital, 75010 Paris, France.
authors: Christophe
authors: C
authors: Hennequin
keywords: Chemotherapy; Gastric cancer; Radiotherapy; Review